Attached files
| file | filename |
|---|---|
| EX-3.1 - AMENDED AND RESTATED ARTICLES OF INCORPORATION - Hydrogen Future Corp | aflb_ex31.htm |
| EX-3.2 - AMENDED AND RESTATED BYLAWS - Hydrogen Future Corp | aflb_ex32.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
September 5, 2013
A5 Laboratories Inc.
(Exact name of registrant as specified in its charter)
|
Nevada
|
333-138927
|
20-5277531
|
||
|
(State or Other Jurisdiction of
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
||
|
Incorporation)
|
2525 Robinhood Street, Suite 1100
Houston, Texas 77005
(Address of Principal Executive Offices)
(713) 465-1001
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On September 5, 2013, A5 Laboratories Inc. (“the Company”) held a special meeting of shareholders. The following table presents the final voting results for the items that were presented for shareholder approval:
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|||||
|
Proposal No. 1
|
||||||||
|
Approve the Amended and Restated Articles of Incorporation of A5 Laboratories Inc.
|
55,249,498 common
100,000,000 preferred
|
1,120,095 common
|
55,261 common
|
--
|
||||
|
Proposal No. 2
|
||||||||
|
Approve the Amended and Restated Bylaws of A5 Laboratories Inc.
|
55,236,873 common
100,000,000 preferred
|
1,111,080 common
|
77,261 common
|
--
|
In summary, the results of the votes were:
(i) The Amended and Restated Articles of Incorporation of A5 Laboratories Inc. were approved; and
(ii) The Amended and Restated Bylaws of A5 Laboratories Inc. were approved.
For additional information on these proposals, please see the Company’s Form 8-K filed with the Securities and Exchange Commission on August 30, 2013.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
Amended and Restated Articles of Incorporation of A5 Laboratories Inc.
|
||
|
Amended and Restated Bylaws of A5 Laboratories Inc.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
A5 LABORATORIES INC.
|
|||
|
(Registrant)
|
|||
|
Dated: September 9, 2013
|
By:
|
/s/ Frank Neukomm
|
|
|
Name:
|
Frank Neukomm
|
||
|
Title:
|
Chairman Chief Executive Officer
|
||
3
INDEX TO EXHIBITS
|
Exhibit No.
|
Description
|
|
|
Amended and Restated Articles of Incorporation of A5 Laboratories Inc.
|
||
|
Amended and Restated Bylaws of A5 Laboratories Inc.
|
4